Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Completed	`NCT00377520` - A Trial for Patients With Advanced/Recurrent Endometrial Cancer	Phase 2
Active, not recruiting	`NCT05602935` - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study	Phase 2
Active, not recruiting	`NCT03911388` - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Phase 1
Active, not recruiting	`NCT03656718` - A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)	Phase 1/Phase 2
Recruiting	`NCT05322486` - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting	`NCT04566952` - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer	Phase 2
Recruiting	`NCT05770102` - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition	Phase 2/Phase 3
Recruiting	`NCT01917279` - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC	Phase 3
Recruiting	`NCT01427400` - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction	Phase 4
Completed	`NCT01472146` - ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer	Phase 2
Completed	`NCT00050414` - A Study of Trabectedin in Patients With Advanced Ovarian Cancer	Phase 2
Active, not recruiting	`NCT01037049` - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks	Phase 2
Recruiting	`NCT04556071` - Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer	Phase 2
Active, not recruiting	`NCT01968109` - An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT02960724` - uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer	Phase 2
Completed	`NCT00562224` - Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients	Phase 1
Completed	`NCT04679675` - Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial	N/A
Completed	`NCT04080843` - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients	Phase 2
Terminated	`NCT04644315` - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Phase 2

NCT number	NCT01629758
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 1
Start date	June 2012
Completion date	December 2014

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms